RPTP Overview
Upcoming Projects (RPTP)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (RPTP)
-
An Analysis of the Market Potential in US of Raptor Pharmaceutical's Quisair (Inhaled Levofloxacin) for Cystic Fibrosis if Approved
Tickers: HZNP, RPTP
Execute By: Oct 19, 2016
Upcoming & Overdue Catalysts (RPTP)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (RPTP)
-
Canada Accepts NDA for Procysbi and Grants Priority Review - Decision on Approval Expected By June 2017
Tickers: RPTP, HZNP
Occurred on: Jun 19, 2017 -
Quinsair for treatment of cystic fibrosis to Commercially Launch in Canada in H2 of 2016
Tickers: RPTP, HZNP
Occurred on: Dec 22, 2016 -
Interim Phase 2 data for RP103 in Mitochondrial Diseases due Q2 of 2016
Ticker: RPTP
Occurred on: Aug 04, 2016 -
Pre-NDA Discussion with FDA for MP-376 in Cystic Fibrosis Scheduled for 2Q 2016
Ticker: RPTP
Occurred on: May 19, 2016 -
Phase 2 second interim analysis of RP 103 for Mitochondial disorders including Leigh syndrome due 1Q 2016
Ticker: RPTP
Occurred on: May 05, 2016 -
Qualified Infectious Disease Product (QIDP) Designation for MP-376 (Inhaled Levofloxacin) for Three Indications
Ticker: RPTP
Occurred on: Mar 16, 2016
Strategic Initiatives (RPTP)
-
Horizon Pharma plc (HZNP) Complete Acquisition of Raptor Pharmaceutical Corp. (RPTP)
Tickers: HZNP, RPTP
Announcement Date: Oct 25, 2016
